Compare
Cytosorbents Corp vs ClearPoint Neuro, Inc. vs Retractable Technologies Inc vs Interpace Biosciences, Inc.
| Latest fiscal year | Cytosorbents Corp CTSO | ClearPoint Neuro, Inc. CLPT | Retractable Technologies Inc RVP | Interpace Biosciences, Inc. IDXG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $37.06M | $36.97M | $38.27M | $38.73M |
| Revenue growth (YoY) | +4.1% | +17.8% | +15.8% | -17.5% |
| Gross margin | 71.5% | 61.4% | 0.1% | 62.3% |
| Operating margin | -39.8% | -65.4% | -55.3% | 10.5% |
| Net margin | -22.1% | -69.1% | -32.8% | 63.5% |
| Net income | -$8.20M | -$25.54M | -$12.57M | $24.57M |
| EPS (Diluted) | -$0.13 | -$0.90 | -$0.43 | $0.89 |
| Operating cash flow | -$12.38M | -$23.93M | -$7.06M | $5.83M |
| Free cash flow | -$12.54M | -$24.45M | n/a | $5.47M |
| Cash & equivalents | $6.25M | $45.92M | $2.59M | $2.50M |
| Total assets | $44.18M | $97.75M | $142.63M | $33.84M |
| Total liabilities | $38.28M | $69.73M | $68.26M | $11.47M |
| Shareholders' equity | $5.90M | $28.02M | $74.38M | $22.36M |
| Return on year-end equity | -138.9% | -91.1% | -16.9% | 109.9% |
| Shares outstanding | 62.80M | 29.37M | 29.94M | 4.43M |
Revenue, most recent five fiscal years
| Fiscal year | Cytosorbents Corp | ClearPoint Neuro, Inc. | Retractable Technologies Inc | Interpace Biosciences, Inc. |
|---|---|---|---|---|
| Latest | $37.06M Ended 2025-12-31 | $36.97M Ended 2025-12-31 | $38.27M Ended 2025-12-31 | $38.73M Ended 2025-12-31 |
| 1 year earlier | $35.59M Ended 2024-12-31 | $31.39M Ended 2024-12-31 | $33.05M Ended 2024-12-31 | $46.93M Ended 2024-12-31 |
| 2 years earlier | $31.08M Ended 2023-12-31 | $23.95M Ended 2023-12-31 | $43.60M Ended 2023-12-31 | $40.04M Ended 2023-12-31 |
| 3 years earlier | $34.69M Ended 2022-12-31 | $20.55M Ended 2022-12-31 | $94.82M Ended 2022-12-31 | $31.84M Ended 2022-12-31 |
| 4 years earlier | $43.17M Ended 2021-12-31 | $16.30M Ended 2021-12-31 | $188.38M Ended 2021-12-31 | $33.12M Ended 2021-12-31 |